Nurix Surges 43% on Roche's $3B Cancer Deal — What Leveraged Traders Need to Know
Nurix's 43% surge on a Roche deal up to $3B validates its protein-degradation platform — but leveraged CFD traders must account for post-spike liquidation risk and heavily back-loaded deal economics before sizing new positions.